John M. Brooks, PhD

home / authors / john-m-brooks-phd

Articles

January 29th 2011

Effects of Health Savings Account Eligible Plans on Utilization and Expenditures

Mary E. Charlton, PhD Barcey T. Levy, PhD, MD Robin R. High, MBA, MA John E. Schneider, PhD John M. Brooks, PhD

The health savings account-eligible design may decrease costs and utilization, but it also may decrease use of preventive services.

September 15th 2008

Metastatic Non–Small Cell Lung Cancer: Costs Associated With Disease Progression

Kathleen M. Fox, MHS, PhD John M. Brooks, PhD Jennifer Kim, PharmD

The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.

Latest Updated Articles

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Jason Porter, MD, an expert on lung cancer

Published: July 24th 2024 | Updated: July 27th 2024

Long-Term Follow-Up from CheckMate 9LA at ASCO 2024

Published: July 24th 2024 | Updated: July 27th 2024

Insights from the TROPION-Lung05 Trial at ASCO 2024

Liz Kwo, MD, MBA, MPH, chief commercial officer, Everly Health, and faculty lecturer, Harvard Medical School

Published: July 24th 2024 | Updated: July 27th 2024

Examining Trends, Future Directions in AI and Health Care

Aspirin tablets dissolving in water | Imaged credit: Victor Moussa - stock.adobe.com

Published: July 15th 2024 | Updated: July 27th 2024

No Sex Differences Identified in Aspirin Dosing for Secondary Prevention of ASCVD

Alfred L. Garfall, MD, an expert on multiple myeloma

Published: July 24th 2024 | Updated: July 27th 2024

Future Directions in the Management of Multiple Myeloma

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions